Loading
An Exact Sciences study that collected blood from people with and without cancer to develop the CancerSEEK blood test.
ASCEND (NCT04213326) is an observational study sponsored by Exact Sciences Corporation. It collected 60 mL blood samples and medical-record data from people with and without cancer to train and test the assay. Results are posted on the registry.
The registry record, read on 29 October 2026, gives its status as completed, with 6,400 participants enrolled, a start on 18 November 2019 and primary completion on 29 January 2021.
Shares Cancerguard, Exact Sciences (Abbott), Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares CancerSEEK, DETECT-A: a blood test plus PET-CT to screen 10,006 women with no symptoms, Cancerguard, Multi-cancer early detection (MCED).
Shares Exact Sciences (Abbott), Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Cancerguard, Exact Sciences (Abbott), Multi-cancer early detection (MCED).
Shares CancerSEEK, DETECT-A: a blood test plus PET-CT to screen 10,006 women with no symptoms, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares CancerSEEK, DETECT-A: a blood test plus PET-CT to screen 10,006 women with no symptoms, Cancerguard, Multi-cancer early detection (MCED).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/